AI assistant
Immuron Ltd Regulatory Filings 2005
35121_rns_2005-10-11_7232f7b3-9269-4225-a819-84a20ee09441.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
October 12th 2005
Company Announcement Office Australian Stock Exchange Ltd (ASX) 4th Floor, 20 Bridge Street Sydney NSW 2000
Dear Sir/Madam,
Please find herewith a copy of "Travelan Receives Green Light To Enter U.S. Market" for release and distribution to the market immediately.
On Behalf Of ANADIS LIMITED
CONOR GRAHAM Managing Director & CEO
Travelan* receives green light to enter US market.
Travelan has been assessed in the United States and given the green light to be sold into the commercially significant North American market.
Research, review and analysis of Anadis' Travelan -hyper immunized colostrum powder- as well as history of use and safety / toxicology evidence, has received US legal opinion that Travelan is in compliance with all US Federal and State regulations for sale in the Dietary and Medical Food categories.
Travelan and Travellers' Diarrhoea
Travelan – Anadis' lead product – is a revolutionary over-the-counter (OTC) preparation scientifically and clinically proven to significantly reduce the risk of getting the medical condition known as Travellers' Diarrhoea (otherwise known as Delhi Belly, Montezuma's Revenge, Tourist Trots and The Flux etc). Travellers' Diarrhoea is described as the number one health problem for international travellers, in terms of frequency and economic impact. Travellers' Diarrhoea is normally accompanied by other clinical features such as nausea, vomiting, abdominal cramps and fever. Travelan is based on antibody technology and not an antibiotic preparation. Unlike conventional treatment medications, Travelan significantly reduces the risk of being affected in the first instance.
Commercial Opportunities for Travelan
With more than 22 million US travellers per year to "High Risk" areas (this figure does not include travel to "medium risk" or "low risk" areas) the US is a very significant market for Anadis. Medical statistics show that, on average, over 40% of travellers will be somehow affected by Travellers' Diarrhoea.
This "green light" is an important and exciting step for the international expansion of Travelan. Anadis is currently in discussions with prospective partners in the US market to begin sales of Travelan at the earliest opportunity.
In addition, Anadis is also actively working on registration in other international markets including Canada, Singapore, Hong Kong, India, Thailand, Taiwan, Malaysia, United Kingdom and Europe.
For more information about Travelan visit www.travelan.com.au
About Anadis Limited:
Anadis, a Melbourne based Biopharmaceutical Company, focused on Nutraceutical and Pharmaceutical product development. Anadis is currently also in the process of commercialising $EV-71$ - a bioactive protein based product against Enterovirus 71, a debilitating polio like disease affecting children in Taiwan and other parts of Asia.
Other products / projects currently under development include:
A set of Bio-Warfare/Respiratory Protection technologies, a project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations, initially focused on short-term immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hay Fever and Asthma.
Bio-Shield 10 a range of "bioshielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market, and research has also begun into an Immune Stimulating Infant Formula initially for the Asian market.
Pyloran, which has been clinically proven to reduce levels of bacteria in the stomach and reduce the symptoms of H.pylori associated gastritis - Anadis is also in early development of a H.pylori vaccine $*$ .
* Prof. Roy Robins-Browne and the Anadis scientific team, congratulate Prof. Barry Marshall and Dr. Robin Warren on their recent Nobel prize for their discovery of the bacterium H.pvlori and its role in gastritis and peptic ulcer disease.
For further information, please contact:
Conor Graham - Chief Executive Officer Email: [email protected] $+61393586388$
Steven Skorobogaty - General Manager Email [email protected] $+61393586388$
Arie Nudel - Investor Relations Email: [email protected] $+61393586388$
Visit our websites: www.anadis.com.au and www.travelan.com.au